Chronic myeloid leukaemia (CML) blockbuster Gleevec has been badly hit by generic ... talked-about developments over recent months was Novartis’ decision to break up its cell and gene therapy ...

In 2001, a Time Magazine cover story touted Novartis’ targeted leukemia treatment Gleevec (imatinib) as a new kind of ...

Imkeldi is a new formulation of imatinib approved as a strawberry-flavored, shelf-stable liquid designed to be more appealing ...

Novartis AG) for adult patients with newly diagnosed Philadelphia chromosome–positive CML in chronic phase. Asciminib is one ...

However, when treated with Gleevec, a TKI that inhibits the Abelson tyrosine kinase (ABL), they showed remarkable improvement ...

The PhALLCON trial compared Iclusig (ponatinib) to imatinib – sold by Novartis as Glivec/Gleevec, but also available as a generic – on top of a reduced-intensity chemotherapy regimen in 230 ...

Novartis produced a compound known as imatinib ... Imatinib (now known as Gleevec) had turned a fatal disease into a manageable condition. Better yet, it showed that you could treat cancer with ...

The only outliers were cABL kinase, which is targeted by imatinib (Gleevec; Novartis) and might therefore be explained by a preference for selectivity over affinity, and HMG-CoA (3-hydroxy-3 ...

In one internal communication cited by the FTC, an unidentified executive noted that patients could get a commonly prescribed treatment for leukemia, a generic version of Novartis’s Gleevec ...

Patents are a big issue as well. After the Gleevec ruling in India, Novartis is seriously considering if and how it will bring new drugs to the country. The Wall Street Journal talked to Novartis ...